Recently, the programmed cell death ligand 1 and human epidermal growth factor receptor 2 have been proven to prolong the survival of patients with GC [4], signifying the feasibility of targeted therapy toward GC [5]. The gene discussed is ERBB2; the disease is gastric cancer.